Efficacy of Alkalinized Lidocaine Compared to Remifentanil on the Incidence of Coughing During Emergence of Anesthesia

Sponsor
Centre hospitalier de l'Université de Montréal (CHUM) (Other)
Overall Status
Completed
CT.gov ID
NCT01451840
Collaborator
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (Other)
85
1
2
9
9.4

Study Details

Study Description

Brief Summary

This study is designed to compare the effects of alkalinized lidocaine in the endotracheal tube cuff to a bolus dose of remifentanil given prior to the emergence of anesthesia:

  • on the incidence of perioperative coughing

  • on the time needed for the emergence of a desflurane-based anesthesia

  • on the incidence of sore throat after extubation.

The investigators hypothesis is that the use of alkalinized lidocaine in the endotracheal tube cuff will reduce the incidence of perioperative coughing after a desflurane-based anesthesia.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Emergence is an important period of general anesthesia during which several problems can occur. Coughing, hypertension, tachycardia and agitation have been observed during emergence of general anesthesia.

Desflurane is a newer volatile agent allowing early recovery from anesthesia. This agent has led to earlier discharge and more rapid resumption of normal activities after surgery. However, an incidence of coughing around 70% has been reported after a desflurane-based anesthesia. Different techniques and drugs have been studied to reduce coughing during emergence.

Among others, the role of lidocaine given intravenously, topically, or intracuff has been studied. The use of intracuff alkalinized lidocaine has been proven effective to reduce the incidence of coughing during emergence of anesthesia.

Furthermore, there is some evidence supporting the administration of intravenous opioids prior to emergence of general anesthesia to reduce perioperative coughing, agitation and hemodynamic stimulation. However, depending on the type of opioids given, this may delay the emergence from anesthesia. The effect of a remifentanil infusion given in combination with isoflurane as the volatile agent has been shown to reduce the incidence of perioperative coughing without delaying the emergence of anesthesia. Bolus doses of remifentanil have also been proven effective to reduce the hemodynamic response to extubation.

The effect of these two modalities (alkalinized lidocaine and remifentanil) have never been compared. This study will assess their efficacy to prevent perioperative coughing after a desflurane-based anesthesia.

Study Design

Study Type:
Interventional
Actual Enrollment :
85 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Efficacy of Alkalinized Lidocaine in the Endotracheal Tube Cuff Compared to a Bolus Dose of Intravenous Remifentanil on the Incidence of Coughing During Emergence of Anesthesia
Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Oct 1, 2012
Actual Study Completion Date :
Oct 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Remifentanil 0.25 mcg/kg

Administration of a bolus dose of intravenous remifentanil before emergence of a desflurane-based anesthesia

Drug: Remifentanil
Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia

Experimental: Alkalinized lidocaine

Administration of alkalinized lidocaine in the endotracheal tube cuff

Drug: Alkalinized lidocaine
Administration of alkalinized lidocaine in the endotracheal tube cuff

Outcome Measures

Primary Outcome Measures

  1. Incidence of coughing during emergence and after extubation [From emergence until 10 minutes after extubation]

Secondary Outcome Measures

  1. Time to emergence [From the discontinuation of Desflurane until extubation]

  2. Incidence of sore throat one hour after extubation [Assessed one hour after extubation]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged 18-80 years

  • Physical status 1-3

  • Patients undergoing elective surgery under general anesthesia requiring oral endotracheal intubation (excluding head and neck surgery)

  • Expected duration of surgery of at least 1.5 hour.

Exclusion Criteria:
  • Current use of ACE inhibitor

  • Chronic cough

  • Asthma or severe pulmonary disease

  • Pulmonary tract infection

  • Anticipated difficult intubation

  • Current use of opioids

  • Current use of cough medicine

  • Contraindication to remifentanil, lidocaine

  • Pregnancy

  • Symptomatic cardiac, renal or hepatic disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier de l'Université de Montréal Montreal Quebec Canada H2L 4M1

Sponsors and Collaborators

  • Centre hospitalier de l'Université de Montréal (CHUM)
  • Centre de Recherche du Centre Hospitalier de l'Université de Montréal

Investigators

  • Principal Investigator: Nathalie Massicotte, MD,FRCPC, Centre hospitalier de l'Université de Montréal (CHUM)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov Identifier:
NCT01451840
Other Study ID Numbers:
  • NM2012-001
First Posted:
Oct 14, 2011
Last Update Posted:
Oct 29, 2012
Last Verified:
Oct 1, 2012
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 29, 2012